Literature DB >> 6717892

Lonidamine: a hyperthermic sensitizer of HeLa cells in culture and of the Meth-A tumor in vivo.

J H Kim, S H Kim, A Alfieri, C W Young, B Silvestrini.   

Abstract

Lonidamine was studied in HeLa cell cultures and BALB/c mice with Meth-A fibrosarcoma. Lonidamine is a hyperthermia sensitizer, both in vivo and in vivo. In vitro the potentiating effects were higher at low pH conditions.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6717892     DOI： 10.1159/000225882

Source DB:  PubMed          Journal:  Oncology        ISSN： 0030-2414            Impact factor:   2.935


  10 in total

1.  Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.

Authors:  G N Schwartz; B A Teicher; J P Eder; T Korbut; S A Holden; G Ara; T S Herman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

2.  Effects of hyperglycemia on lonidamine-induced acidification and de-energization of human melanoma xenografts and sensitization to melphalan.

Authors:  Kavindra Nath; David S Nelson; Daniel F Heitjan; Rong Zhou; Dennis B Leeper; Jerry D Glickson
Journal:  NMR Biomed       Date:  2015-03       Impact factor: 4.044

3.  Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.

Authors:  K W Rosbe; T W Brann; S A Holden; B A Teicher; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin.

Authors:  Kavindra Nath; David S Nelson; Daniel F Heitjan; Dennis B Leeper; Rong Zhou; Jerry D Glickson
Journal:  NMR Biomed       Date:  2014-12-12       Impact factor: 4.044

5.  Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification.

Authors:  O Ben-Yoseph; J C Lyons; C W Song; B D Ross
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

6.  Kinetic and survival response of the M14 cell line to lonidamine associated with adriamycin or hyperthermia.

Authors:  G Starace; G Badaracco; A Bertuzzi; A Gandolfi; C Greco; M D Totaro; R Vitelli; G Zupi
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

7.  Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.

Authors:  R J Popert; J R Masters; M Coptcoat; G Zupi
Journal:  Urol Res       Date:  1995

8.  Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide.

Authors:  Kavindra Nath; David S Nelson; Jeffrey Roman; Mary E Putt; Seung-Cheol Lee; Dennis B Leeper; Jerry D Glickson
Journal:  Anticancer Res       Date:  2017-07       Impact factor: 2.480

Review 9.  The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment.

Authors:  Yaxin Huang; Guohui Sun; Xiaodong Sun; Feifan Li; Lijiao Zhao; Rugang Zhong; Yongzhen Peng
Journal:  Cancers (Basel)       Date:  2020-11-11       Impact factor: 6.639

10.  Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin.

Authors:  Kavindra Nath; Jeffrey Roman; David S Nelson; Lili Guo; Seung-Cheol Lee; Stepan Orlovskiy; Kevin Muriuki; Daniel F Heitjan; Stephen Pickup; Dennis B Leeper; Ian A Blair; Mary E Putt; Jerry D Glickson
Journal:  Sci Rep       Date:  2018-10-02       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.